Eagle Pharmaceuticals Stock Buy Hold or Sell Recommendation

EGRX Stock  USD 5.24  0.23  4.59%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eagle Pharmaceuticals is 'Strong Sell'. Macroaxis provides Eagle Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding EGRX positions. The advice algorithm takes into account all of Eagle Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Eagle Pharmaceuticals' buy or sell advice are summarized below:
Real Value
7.99
Target Price
17
Hype Value
5.24
Market Value
5.24
Naive Value
4.79
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Eagle Pharmaceuticals given historical horizon and risk tolerance towards Eagle Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Eagle Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out Eagle Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.
In addition, we conduct extensive research on individual companies such as Eagle and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Execute Eagle Pharmaceuticals Buy or Sell Advice

The Eagle recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eagle Pharmaceuticals. Macroaxis does not own or have any residual interests in Eagle Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eagle Pharmaceuticals' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Eagle PharmaceuticalsBuy Eagle Pharmaceuticals
Strong Sell

Market Performance

Very WeakDetails

Volatility

Slightly riskyDetails

Hype Condition

StaleDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Very SmallDetails

Economic Sensitivity

Actively responds to the marketDetails

Investor Sentiment

ImpartialDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Possible ManipulatorDetails
For the selected time horizon Eagle Pharmaceuticals has a Mean Deviation of 3.76, Semi Deviation of 4.39, Standard Deviation of 4.75, Variance of 22.55, Downside Variance of 21.99 and Semi Variance of 19.27
We provide trade advice to complement the prevailing expert consensus on Eagle Pharmaceuticals. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Eagle Pharmaceuticals is not overpriced, please confirm all Eagle Pharmaceuticals fundamentals, including its number of shares shorted, current ratio, working capital, as well as the relationship between the ebitda and target price . Given that Eagle Pharmaceuticals has a price to earning of 40.52 X, we urge you to verify Eagle Pharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Eagle Pharmaceuticals Trading Alerts and Improvement Suggestions

Eagle Pharmaceuticals generated a negative expected return over the last 90 days
Eagle Pharmaceuticals has high historical volatility and very poor performance
Eagle Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Over 86.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Eagle Pharmaceuticals Stock Price Crosses Below 200-Day Moving Average of 8.94 - MarketBeat

Eagle Pharmaceuticals Returns Distribution Density

The distribution of Eagle Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Eagle Pharmaceuticals' future price movements. The chart of the probability distribution of Eagle Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Eagle Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eagle Pharmaceuticals returns is essential to provide solid investment advice for Eagle Pharmaceuticals.
Mean Return
0.19
Value At Risk
-7.11
Potential Upside
7.29
Standard Deviation
4.75
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eagle Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Eagle Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Eagle Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eagle Pharmaceuticals backward and forwards among themselves. Eagle Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eagle Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Acadian Asset Management Llc2023-12-31
287.6 K
Dimensional Fund Advisors, Inc.2023-12-31
246.5 K
J. Goldman & Co Lp2023-12-31
246.4 K
Geode Capital Management, Llc2023-12-31
225.3 K
State Street Corporation2023-12-31
222.6 K
Two Sigma Advisers, Llc2023-12-31
222 K
Assenagon Asset Management Sa2023-12-31
217.7 K
Two Sigma Investments Llc2023-12-31
207.6 K
Bank Of America Corp2023-12-31
187 K
Blackrock Inc2023-12-31
984.9 K
Hhg Plc2023-12-31
775.5 K
Note, although Eagle Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Eagle Pharmaceuticals Cash Flow Accounts

201920202021202220232024 (projected)
Change To Inventory1.7M(1.5M)(13.8M)(8.3M)(7.5M)(7.1M)
Change In Cash31.0M(6.6M)(5.5M)(42.3M)(38.1M)(36.2M)
Free Cash Flow55.2M48.8M27.9M50.5M58.1M61.0M
Depreciation4.7M4.8M3.8M12.0M13.8M14.5M
Other Non Cash Items480K8.7M7.6M11.3M13.0M13.7M
Capital Expenditures777K747K323K178K160.2K152.2K
Net Income14.3M12.0M(8.6M)35.6M41.0M43.0M
End Period Cash Flow109.8M103.2M97.7M55.3M63.6M73.0M
Investments(777K)(18.2M)(5.3M)(86.8M)(78.1M)(74.2M)
Change Receivables18.5M(3.1M)9.5M(30.8M)(35.5M)(33.7M)
Net Borrowings(6.3M)(5M)(8M)11.4M10.3M16.2M
Change To Netincome22.2M28.5M21.4M17.7M20.4M16.0M

Eagle Pharmaceuticals Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eagle Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eagle Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eagle stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over NYSE Composite
-0.02
β
Beta against NYSE Composite1.67
σ
Overall volatility
4.72
Ir
Information ratio 0.01

Eagle Pharmaceuticals Volatility Alert

Eagle Pharmaceuticals exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eagle Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eagle Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Eagle Pharmaceuticals Fundamentals Vs Peers

Comparing Eagle Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eagle Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Eagle Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eagle Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eagle Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Eagle Pharmaceuticals by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Eagle Pharmaceuticals to competition
FundamentalsEagle PharmaceuticalsPeer Average
Return On Equity0.0488-0.31
Return On Asset0.0663-0.14
Profit Margin0.05 %(1.27) %
Operating Margin0.16 %(5.51) %
Current Valuation121.18 M16.62 B
Shares Outstanding12.96 M571.82 M
Shares Owned By Insiders12.02 %10.09 %
Shares Owned By Institutions86.36 %39.21 %
Number Of Shares Shorted1.16 M4.71 M
Price To Earning40.52 X28.72 X
Price To Book0.26 X9.51 X
Price To Sales0.27 X11.42 X
Revenue316.61 M9.43 B
Gross Profit221.67 M27.38 B
EBITDA65.48 M3.9 B
Net Income35.64 M570.98 M
Cash And Equivalents36.56 M2.7 B
Cash Per Share2.75 X5.01 X
Total Debt62.47 M5.32 B
Debt To Equity0.23 %48.70 %
Current Ratio1.78 X2.16 X
Book Value Per Share19.25 X1.93 K
Cash Flow From Operations50.7 M971.22 M
Short Ratio8.17 X4.00 X
Earnings Per Share0.85 X3.12 X
Price To Earnings To Growth0.91 X4.89 X
Target Price17.0
Number Of Employees13418.84 K
Beta0.43-0.15
Market Capitalization68.55 M19.03 B
Total Asset406.16 M29.47 B
Retained Earnings111.5 M9.33 B
Working Capital77.67 M1.48 B
Note: Payment of 2119 shares by Scott Tarriff of Eagle Pharmaceuticals subject to Rule 16b-3 [view details]

Eagle Pharmaceuticals Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eagle . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Eagle Pharmaceuticals Buy or Sell Advice

When is the right time to buy or sell Eagle Pharmaceuticals? Buying financial instruments such as Eagle Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2021 2022 2023 2024 (projected)
Short and Long Term Debt Total25.6M62.5M71.8M41.6M
Total Assets253.7M406.2M467.1M490.4M

Use Investing Ideas to Build Portfolios

In addition to having Eagle Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Most Shorted Equities Thematic Idea Now

Most Shorted Equities
Most Shorted Equities Theme
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 194 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Eagle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eagle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eagle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eagle Pharmaceuticals Stock:
Check out Eagle Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.
You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Eagle Stock analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.87)
Earnings Share
0.85
Revenue Per Share
19.684
Quarterly Revenue Growth
(0.13)
Return On Assets
0.0663
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.